ASX:PIQ

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Proteomics International Laboratories

Market Cap

AU$128.4m

Last Updated

2021/07/27 17:27 UTC

Data Sources

Company Financials

Executive Summary

Proteomics International Laboratories Limited operates as a medical technology company with a focus on the area of proteomics. More Details


Snowflake Analysis

Flawless balance sheet with weak fundamentals.

Share Price & News

How has Proteomics International Laboratories's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PIQ is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: PIQ's weekly volatility (10%) has been stable over the past year.


Market Performance


7 Day Return

19.6%

PIQ

-1.4%

AU Life Sciences

2.0%

AU Market


1 Year Return

106.8%

PIQ

2.6%

AU Life Sciences

26.0%

AU Market

Return vs Industry: PIQ exceeded the Australian Life Sciences industry which returned 2.6% over the past year.

Return vs Market: PIQ exceeded the Australian Market which returned 26% over the past year.


Shareholder returns

PIQIndustryMarket
7 Day19.6%-1.4%2.0%
30 Day31.9%-1.7%1.4%
90 Day3.4%-27.9%4.3%
1 Year106.8%106.8%2.8%2.6%30.6%26.0%
3 Year328.1%328.1%63.7%56.5%33.4%17.2%
5 Year408.3%408.3%-2.9%-13.7%65.0%32.8%

Long-Term Price Volatility Vs. Market

How volatile is Proteomics International Laboratories's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Proteomics International Laboratories undervalued compared to its fair value and its price relative to the market?

15.44x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate PIQ's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate PIQ's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: PIQ is unprofitable, so we can't compare its PE Ratio to the Global Life Sciences industry average.

PE vs Market: PIQ is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PIQ's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PIQ is overvalued based on its PB Ratio (15.4x) compared to the AU Life Sciences industry average (4.6x).


Future Growth

How is Proteomics International Laboratories forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

15.3%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Proteomics International Laboratories has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Proteomics International Laboratories performed over the past 5 years?

-9.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PIQ is currently unprofitable.

Growing Profit Margin: PIQ is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PIQ is unprofitable, and losses have increased over the past 5 years at a rate of 9.5% per year.

Accelerating Growth: Unable to compare PIQ's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PIQ is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (44%).


Return on Equity

High ROE: PIQ has a negative Return on Equity (-29.08%), as it is currently unprofitable.


Financial Health

How is Proteomics International Laboratories's financial position?


Financial Position Analysis

Short Term Liabilities: PIQ's short term assets (A$8.1M) exceed its short term liabilities (A$753.4K).

Long Term Liabilities: PIQ's short term assets (A$8.1M) exceed its long term liabilities (A$350.0K).


Debt to Equity History and Analysis

Debt Level: PIQ is debt free.

Reducing Debt: PIQ has no debt compared to 5 years ago when its debt to equity ratio was 45.2%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PIQ has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: PIQ has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 8.7% each year


Dividend

What is Proteomics International Laboratories's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PIQ's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PIQ's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PIQ's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PIQ's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PIQ's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.1yrs

Average management tenure


CEO

Richard Lipscombe

7.08yrs

Tenure

AU$299,231

Compensation

Dr. Richard John Lipscombe, Ph.D (London), MA (Oxford), co-founded Proteomics International Laboratories Limited in 2001 and serves as its Managing Director and Director since June 09, 2014. Mr. Lipscombe ...


CEO Compensation Analysis

Compensation vs Market: Richard's total compensation ($USD221.01K) is about average for companies of similar size in the Australian market ($USD270.68K).

Compensation vs Earnings: Richard's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: PIQ's management team is considered experienced (3.1 years average tenure).


Board Members

Experienced Board: PIQ's board of directors are considered experienced (5.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13.9%.


Top Shareholders

Company Information

Proteomics International Laboratories Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Proteomics International Laboratories Limited
  • Ticker: PIQ
  • Exchange: ASX
  • Founded: 2001
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$128.351m
  • Shares outstanding: 105.21m
  • Website: https://www.proteomics.com.au

Location

  • Proteomics International Laboratories Limited
  • QEII Medical Centre
  • QQ Block
  • Perth
  • Western Australia
  • 6009
  • Australia

Listings


Biography

Proteomics International Laboratories Limited operates as a medical technology company with a focus on the area of proteomics. It provides PromarkerD, a predictive test for diabetic kidney disease; and dev...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/07/27 17:27
End of Day Share Price2021/07/27 00:00
Earnings2020/12/31
Annual Earnings2020/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.